
Lamberto Andreotti new head of Bristol-Myers Squibb
pharmafile | March 4, 2010 | Appointment | Research and Development, Sales and Marketing | BMS, appointment, research and development, sales and marketing
Bristol-Myers Squibb has appointed Lamberto Andreotti its new chief executive with effect from 4 May, succeeding James Cornelius who will remain as the company’s chairman.
Andreotti said: “Jim successfully led our transformation into a next-generation biopharma leader with his strategic leadership and consistent focus on delivering our commitments. I am personally grateful for this opportunity to lead Bristol-Myers Squibb in the next phase of our biopharma journey.
Andreotti is currently responsible for the BMS’ global pharmaceutical business, holding the roles of president and chief operating officer.
He has been with the company for 12 years in senior leadership roles, both internationally and in the US. Prior to joining BMS he held senior roles at KABI Pharmacia and then at Pharmacia & Upjohn.
“While challenges lie ahead, we are confident we can overcome them as we continue to successfully execute and deliver operationally, financially and strategically to maximise our future opportunities. As we succeed, the ultimate beneficiaries are patients who we help prevail against serious diseases,” he added.
Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …






